Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting being held 3-7 May 2026 in Denver, Colorado, as well as a company presentation at Eyecelerator @ ARVO on 1 May 2026.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks